ClinicalTrials.gov
public full text
Public Domain
DAS181 for STOP COVID-19
It is a multicenter, randomized, placebo-controlled, double-blind study. The study population is defined as subjects diagnosed with lower respiratory tract COVID-19 who require supplemental oxygen ≥2 LPM at the time of randomization.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- The Canadian Cohort Obstructive Lung Disease#869811
- The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease#159200
- Report of the eighteenth annual meeting of the Global Alliance against Chronic Respiratory Diseases: virtual meeting, 28 October 2025#129088
- Influenza Antiviral DAS181-F03#1030077
- A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis#887427
Record · ID 1140650
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive